Titre:
  • Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
Auteur:Da Costa Pereira Pinto, Ana Catarina; Ades Moraes, Felipe; Azambuja, Evandro; Piccart-Gebhart, Martine
Informations sur la publication:Breast, 22, S2, page (S152-S155)
Statut de publication:Publié, 2013-08
Sujet CREF:Chirurgie
Mots-clés:Adjuvant treatment
Chemotherapy
Early breast cancer
HER-2 positive
Intravenous trastuzumab
Subcutaneous trastuzumab
MeSH keywords:Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage
Breast Neoplasms -- drug therapy -- genetics -- mortality -- pathology
Chemotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Injections, Subcutaneous
Mastectomy, Segmental -- methods
Middle Aged
Neoplasm Recurrence, Local -- mortality -- pathology -- therapy
Prognosis
Randomized Controlled Trials as Topic
Receptor, ErbB-2 -- drug effects -- genetics -- metabolism
Survival Analysis
Treatment Outcome
Tumor Markers, Biological -- analysis -- genetics
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0960-9776
info:doi/10.1016/j.breast.2013.07.029
info:pii/S0960977613001641
info:scp/84884724778
info:pmid/24074778